AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27605230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no COX-2 inhibitor)
Number of subjects: 23
Study 25612162 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconal blockade with ultrasound guidance (n = 69)
Number of subjects: 129
Study 25612162 — intervention group
Group type: COMPARATOR
Intervention: Periconal blockade without ultrasound guidance (n = 60)
Number of subjects: 129
Study 23359230 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 99
Study 23359230 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 99
Study 22045673 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFNα-2a 180 μg/week for 48 weeks
Number of subjects: 544
Study 22045673 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFNα-2a 90 μg/week for 24 weeks
Number of subjects: 544
Study 22045673 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFNα-2a 90 μg/week for 48 weeks
Number of subjects: 544
Study 22045673 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFNα-2a 180 μg/week for 24 weeks
Number of subjects: 544
Study 20087260 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with 4 cycles of carboplatine and etoposide followed by conformal radiotherapy (RT)
Number of subjects: 85
Study 20087260 — intervention group
Group type: COMPARATOR
Intervention: Concurrent treatment with cisplatine and etoposide and conformal RT followed by two cycles of consolidation chemotherapy of carboplatine and etoposide
Number of subjects: 85
Study 16339287 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocating syringe
Number of subjects: 100
Study 16339287 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 100
Study 16339287 — intervention group
Group type: EXPERIMENTAL
Intervention: Both syringes
Number of subjects: 100
Study 15318539 — intervention group
Group type: EXPERIMENTAL
Intervention: Profenid (ketoprofen)
Number of subjects: 60
Study 15318539 — intervention group
Group type: COMPARATOR
Intervention: Veral (diclofenac)
Number of subjects: 60
Study 10960939 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine in combination with cisplatin
Number of subjects: 0
Study 10960939 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cisplatin-based gemcitabine doublet combinations
Number of subjects: 0
Study 9665617 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation of the right hippocampal formation during word priming
Number of subjects: 13
Study 8034872 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ST segment resolution (> or = 70%)
Number of subjects: 1817
Study 8034872 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ST segment resolution (< 70% to 30%)
Number of subjects: 1817
Study 8034872 — intervention group
Group type: EXPERIMENTAL
Intervention: No ST segment resolution (< 30% to > 0%)
Number of subjects: 1817
Study 2920504 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra
Number of subjects: 0
Study 2920504 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride oil
Number of subjects: 0
Study 2920504 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 0
Study 31937362 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (kindergarten-based intervention to increase vegetable intake)
Number of subjects: 633
Study 30488617 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg twice a day) plus Amantadine (100 mg daily)
Number of subjects: 100
Study 30488617 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (100 mg twice a day) plus Placebo
Number of subjects: 100
Study 29798120 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii combined with levocetirizine hydrochloride
Number of subjects: 90
Study 29798120 — intervention group
Group type: COMPARATOR
Intervention: Levocetirizine hydrochloride (control group)
Number of subjects: 90
Study 26151090 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast treatment
Number of subjects: 27
Study 26151090 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27
Study 23324437 — intervention group
Group type: EXPERIMENTAL
Intervention: nateglinide
Number of subjects: 40
Study 23324437 — intervention group
Group type: EXPERIMENTAL
Intervention: acarbose
Number of subjects: 40
Study 23324437 — intervention group
Group type: COMPARATOR
Intervention: Control (BMI-matched normoglycemic subjects)
Number of subjects: 40
Study 21454915 — intervention group
Group type: EXPERIMENTAL
Intervention: Mint drink 3 times a day for 1 week
Number of subjects: 24
Study 21454915 — intervention group
Group type: COMPARATOR
Intervention: Off-menthol (avoiding menthol-containing products and mint drink) for 1 week
Number of subjects: 24
Study 18444813 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine
Number of subjects: 26
Study 16927225 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal limiting membrane (ILM) peeling
Number of subjects: 10
Study 16927225 — intervention group
Group type: COMPARATOR
Intervention: No ILM peeling (Control)
Number of subjects: 10
Study 14535877 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 8 weeks
Number of subjects: 43
Study 14535877 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 43
Study 11098486 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT plus leucovorin
Number of subjects: 1530
Study 11098486 — intervention group
Group type: COMPARATOR
Intervention: 5-FU plus leucovorin
Number of subjects: 1530
Study 9408065 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (12.5 mg once daily)
Number of subjects: 15
Study 9408065 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (300 mg b.i.d.)
Number of subjects: 15
Study 9408065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8229143 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotape of consultation
Number of subjects: 142
Study 8229143 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotape describing cancer in general terms
Number of subjects: 142
Study 8229143 — intervention group
Group type: COMPARATOR
Intervention: No tape
Number of subjects: 142
Study 3807243 — intervention group
Group type: EXPERIMENTAL
Intervention: Fornix-based flap
Number of subjects: 61
Study 3807243 — intervention group
Group type: COMPARATOR
Intervention: Limbus-based flap
Number of subjects: 61
Study 29764706 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban monotherapy
Number of subjects: 2200
Study 29764706 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban plus an antiplatelet drug (aspirin, clopidogrel, or prasugrel)
Number of subjects: 2200
Study 27740618 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural beat music (BB)
Number of subjects: 141
Study 27740618 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain music intervention (MI)
Number of subjects: 141
Study 27740618 — intervention group
Group type: COMPARATOR
Intervention: Control group (ear phones with no music)
Number of subjects: 141
Study 25007667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway (NPA)
Number of subjects: 216
Study 25007667 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NPA)
Number of subjects: 216
Study 22554994 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with 200g force after acid and enzyme treatment
Number of subjects: 4
Study 22554994 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with 300g force after acid and enzyme treatment
Number of subjects: 4
Study 22554994 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with 400g force after acid and enzyme treatment
Number of subjects: 4
Study 22554994 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brushing)
Number of subjects: 4
Study 20715524 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 18
Study 20715524 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 18
Study 18036846 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene block (ISB)
Number of subjects: 60
Study 18036846 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial bursa block (SBB)
Number of subjects: 60
Study 18036846 — intervention group
Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 60
Study 16194498 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly home visits with intercalated phone calls from trained nursing staff
Number of subjects: 300
Study 11792880 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-1.2B6-Fab
Number of subjects: 26
Study 11792880 — intervention group
Group type: COMPARATOR
Intervention: (99m)Tc-oxidronate (99m)Tc-HDP
Number of subjects: 26
Study 11792880 — intervention group
Group type: COMPARATOR
Intervention: (99m)Tc-HDP
Number of subjects: 26
Study 10640164 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA/E2C (Lunelle Monthly Contraceptive Injection)
Number of subjects: 1103
Study 10640164 — intervention group
Group type: COMPARATOR
Intervention: NET/EE (Ortho-Novum 7/7/7)
Number of subjects: 1103
Study 10640164 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA/E2C
Number of subjects: 1103
Study 10640164 — intervention group
Group type: COMPARATOR
Intervention: NET/EE
Number of subjects: 1103
Study 10640164 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA/E2C and NET/EE
Number of subjects: 1103
Study 7856526 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil (1,200 mg/day)
Number of subjects: 45
Study 7856526 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin (20 mg/day)
Number of subjects: 45
Study 1950173 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program 'Gesund leben macht Spass' (Healthy living is fun), a 7-week program.
Number of subjects: 413
Study 1950173 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program 'Gesund leben macht Spass' (Healthy living is fun)
Number of subjects: 413
Study 1950173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 413
Study 7000229 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage for 24 hours in complicated hernias
Number of subjects: 301
Study 7000229 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage for 24 hours in simple hernias
Number of subjects: 301
Study 7000229 — intervention group
Group type: COMPARATOR
Intervention: Control group (no suction drainage) in complicated hernias
Number of subjects: 301
Study 7000229 — intervention group
Group type: COMPARATOR
Intervention: Control group (no suction drainage) in simple hernias
Number of subjects: 301
Study 30929965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacrycon® eye drops
Number of subjects: 0
Study 28583879 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation during pregnancy (F-Ca)
Number of subjects: 447
Study 28583879 — intervention group
Group type: COMPARATOR
Intervention: Placebo during pregnancy (F-P)
Number of subjects: 447
Study 28583879 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation during pregnancy (M-Ca)
Number of subjects: 447
Study 28583879 — intervention group
Group type: COMPARATOR
Intervention: Placebo during pregnancy (M-P)
Number of subjects: 447
Study 25963404 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed (FS) 40 g daily for 4 weeks
Number of subjects: 15
Study 23889312 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Cancer Group (CCG) modified Berlin‐Frankfurt‐Muenster (BFM) acute lymphoblastic leukaemia (ALL) regimen with intensified intrathecal (IT) methotrexate (MTX) (Arm A1)
Number of subjects: 254
Study 23889312 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Cancer Group (CCG) modified Berlin‐Frankfurt‐Muenster (BFM) acute lymphoblastic leukaemia (ALL) regimen with intensified intrathecal (IT) methotrexate (MTX) and intensification (Arm A2)
Number of subjects: 254
Study 23889312 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted non‐Hodgkin lymphoma/BFM-95 therapy with high dose MTX in interim maintenance but no IT‐MTX in maintenance (Arm B1)
Number of subjects: 254
Study 23889312 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted non‐Hodgkin lymphoma/BFM-95 therapy with high dose MTX in interim maintenance but no IT‐MTX in maintenance and intensification (Arm B2)
Number of subjects: 254
Study 23889312 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS positive patients (n = 12)
Number of subjects: 254
Study 23889312 — intervention group
Group type: COMPARATOR
Intervention: CNS‐negative patients
Number of subjects: 254
Study 21078700 — intervention group
Group type: EXPERIMENTAL
Intervention: diacutaneous fibrolysis
Number of subjects: 50
Study 21078700 — intervention group
Group type: COMPARATOR
Intervention: placebo diacutaneous fibrolysis
Number of subjects: 50
Study 19930870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI) screening
Number of subjects: 107
Study 16501393 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient/Residential treatment
Number of subjects: 274
Study 16501393 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 274
Study 16501393 — intervention group
Group type: EXPERIMENTAL
Intervention: Any Treatment
Number of subjects: 274
Study 16501393 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual Help Groups
Number of subjects: 274
Study 16501393 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential/Inpatient treatment
Number of subjects: 274
Study 15255797 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal methadone (10 mg d(5)‐methadone‐HCl rectally)
Number of subjects: 7
Study 15255797 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone (10 mg d(0)‐methadone orally)
Number of subjects: 7
Study 11359593 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg.kg‐1 ketamine
Number of subjects: 50
Study 11359593 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg.kg‐1 morphine
Number of subjects: 50
Study 9381265 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA nebulization every 12 hours for 3 months
Number of subjects: 49
Study 9381265 — intervention group
Group type: COMPARATOR
Intervention: Placebo nebulization every 12 hours for 3 months
Number of subjects: 49
Study 9381265 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA nebulization
Number of subjects: 49
Study 9381265 — intervention group
Group type: COMPARATOR
Intervention: Placebo nebulization
Number of subjects: 49
Study 8324915 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa 100 mg
Number of subjects: 12
Study 8324915 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 12
Study 8324915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8324915 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion (0.9%)
Number of subjects: 12
Study 3540308 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment program 1
Number of subjects: 75
Study 3540308 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment program 2
Number of subjects: 75
Study 3540308 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment program 3
Number of subjects: 75
Study 31171725 — intervention group
Group type: EXPERIMENTAL
Intervention: Program with empathy exercise
Number of subjects: 370
Study 31171725 — intervention group
Group type: COMPARATOR
Intervention: Program without empathy exercise
Number of subjects: 370
Study 30208589 — intervention group
Group type: EXPERIMENTAL
Intervention: +LNS
Number of subjects: 20
Study 30208589 — intervention group
Group type: COMPARATOR
Intervention: -LNS
Number of subjects: 20
Study 27454264 — intervention group
Group type: COMPARATOR
Intervention: IV ibuprofen alone (800 mg at induction, 800 mg every 6 hours for up to 5 days)
Number of subjects: 78
Study 27454264 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen (800 mg at induction, 800 mg every 6 hours for up to 5 days) + IV acetaminophen (1000 mg at closure, 800 mg + 1000 mg every 6 hours for up to 5 days)
Number of subjects: 78
Study 27454264 — intervention group
Group type: COMPARATOR
Intervention: IV ibuprofen alone
Number of subjects: 78
Study 27454264 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen + IV acetaminophen
Number of subjects: 78
Study 23845320 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression stockings and subcutaneous injection of unfractionated heparin (unless contraindicated)
Number of subjects: 181
Study 23845320 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of restraint
Number of subjects: 181
Study 23845320 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive sedation
Number of subjects: 181
Study 23845320 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic dosage
Number of subjects: 181
Study 23845320 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent medical hospitalization
Number of subjects: 181
Study 22407510 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 63
Study 22407510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 19863495 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mL of milk fermented with Lactobacillus paracasei, ssp. paracasei F19, Lactobacillus acidophilus La5, and Bifidobacterium lactis Bb12 (Cultura; active)
Number of subjects: 74
Study 19863495 — intervention group
Group type: COMPARATOR
Intervention: Acidified milk without probiotic bacteria (control)
Number of subjects: 74
Study 19863495 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study 19863495 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 74
Study 18829508 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (60-75 mg/m² every 21 days) + Atrasentan (10 mg daily starting on day 3)
Number of subjects: 31
Study 16485512 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 16485512 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting lipophilic ACE-inhibitors
Number of subjects: 0
Study 12452468 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg gemeprost vaginal pessary every 6 hours for 18 hours
Number of subjects: 100
Study 12452468 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 200 microg misoprostol tablets vaginally followed by 2 x 200 microg misoprostol tablets orally every 3 hours for 12 hours
Number of subjects: 100
Study 10599982 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 25
Study 10599982 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (fluvastatin 40 mg/d and gemfibrozil)
Number of subjects: 25
Study 10599982 — intervention group
Group type: COMPARATOR
Intervention: Normolipidemic controls
Number of subjects: 25
Study 7547039 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 ml preload of crystalloid solution
Number of subjects: 60
Study 7547039 — intervention group
Group type: COMPARATOR
Intervention: 200 ml preload of crystalloid solution
Number of subjects: 60
Study 1743319 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone 300 mg
Number of subjects: 60
Study 1743319 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone 200 mg
Number of subjects: 60
Study 1743319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1743319 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (300 mg, 200 mg, placebo)
Number of subjects: 60
Study 1743319 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous E2 and treatment P concentrations
Number of subjects: 60
Study 7094642 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (8 mg)
Number of subjects: 21
Study 7094642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 21
Study 7094642 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 21
Study 30740935 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-enhanced monitoring
Number of subjects: 166
Study 30740935 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 166
Study 30949875 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise (45 min bicycle test)
Number of subjects: 26
Study 30949875 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of exercise intervention
Number of subjects: 26
Study 30949875 — intervention group
Group type: COMPARATOR
Intervention: Baseline syndecan-4
Number of subjects: 26
Study 30949875 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA levels in adipose tissue
Number of subjects: 26
Study 30949875 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA levels in skeletal muscle
Number of subjects: 26
Study 27931137 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil-rich diet
Number of subjects: 17
Study 27931137 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 17
Study 27488278 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPIRE-Group
Number of subjects: 481
Study 27488278 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVE!
Number of subjects: 481
Study 27488278 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPIRE-Phone
Number of subjects: 481
Study 24342820 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive design in phase II trial
Number of subjects: 0
Study 24342820 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term biomarker
Number of subjects: 0
Study 24342820 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive design
Number of subjects: 0
Study 21936751 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks buprenorphine/naloxone (BUP; N = 74)
Number of subjects: 152
Study 21936751 — intervention group
Group type: COMPARATOR
Intervention: 2-week detoxification with buprenorphine/naloxone (DETOX; N = 78)
Number of subjects: 152
Study 21936751 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensation of $5 for weekly urine drug screens and self-reported drug use information, $75 for extensive assessments at weeks 4, 8, and 12
Number of subjects: 152
Study 19246421 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT/A)
Number of subjects: 18
Study 19246421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17580725 — intervention group
Group type: EXPERIMENTAL
Intervention: Aided performance with hearing aids
Number of subjects: 108